Title
Category
Credits
Event date
Cost
  • Primary Care
  • Acute Care
  • Mental Health
  • Pharmacology CE
  • Psychopharmacology CE
  • Contact hours
$15.00
0.75 NAPNAP Pharmacology Contact Hour, and 0.75 Psychopharmacology Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is 7.5$ for NAPNAP Members. For non- members, this continuing education activity rate is 15$. An extensive review will provide the participant with up-to-date information about commonly used antidepressants and atypical antipsychotics.
  • Primary Care
  • Mental Health
  • Pharmacology CE
  • Psychopharmacology CE
  • Contact hours
$30.00
1.25 NAPNAP contact hour, of which 0.25 is Pharmacology and 0.25 Psychopharmacology. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is 15$ for NAPNAP Members. For non- members, this continuing education activity rate is 30$. The course will review disruptive behavior disorders in childhood, including oppositional defiant disorder and conduct disorder. Case studies will include “normal-but-challenging” child behaviors as well as cases delineating diagnostic criteria for these disorders. The presenter will introduce behavioral therapy approaches, including Parent Child Interaction Therapy.
  • Primary Care
  • Pharmacology CE
  • Psychopharmacology CE
  • Controlled Substances CE
  • Contact hours
$10.00
0.5 contact hour of which 0.5 contain pharmacology content and 0.5 controlled substances.This continuing education activity is offered free to NAPNAP Members. For non- members, this continuing education activity rate is $10. Urine drug screening (UDS) is a laboratory test frequently used to screen for drugs of abuse, monitor for medication compliance, evaluate for suspected drug intoxication or overdose, and in office-based pain contracts (Kale, 2019; Standridge, Adams, & Zotos, 2010). In children and adolescents,UDS may be used to prevent substance use, evaluate for suspected drug use or intoxication, or as part of substance abuse treatment (Levy & Siqueira, 2014). When using UDS as a tool to make clinical decisions about high-risk medications, it is important to understand the differences between UDS testing modalities, common causes of falsepositive or false-negative results, and the detection window of specific medications. There are two commonly used types of UDS available: immunoassay and gas chromatography/ mass spectrometry (GC-MS; Kale, 2019).
  • Primary Care
  • Acute Care
  • Pharmacology CE
  • Psychopharmacology CE
$125.00
7.0 NAPNAP Pharmacology Contact Hour, and 0.75 Psychopharmacology Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $55 for NAPNAP Members. For non- members, this continuing education activity rate is $125. Current pediatric prescribing recommendations will be reviewed. An extensive review and update will provide the participant with an improved understanding of therapeutic benefits, as well as potential risks of medications prescribed for children, including efficacy, safety and prescribing recommendations. Drugs abused by adolescents, nutraceuticals used with children, updates on treatment guidelines and changes in drug labeling will be also reviewed.
  • Primary Care
  • Mental Health
  • Pharmacology CE
  • Psychopharmacology CE
  • Controlled Substances CE
  • Contact hours
$10.00
1.0 NAPNAP Contact Hour 0.5 Pharmacology Hours 1.0 Psychopharmacology 0.5 controlled substance. This continuing education activity is offered free to NAPNAP Members. For non- members, this continuing education activity rate is $10. The purpose of this presentation is to have a case-based discussion to increase primary care provider (PCP) confidence in caring for children with ADHD symptoms who have other co-morbidities and those who do not have successful clinical response to first medication use. Included in the discussion are the diagnostic criteria for ADHD, anxiety, autism and explosive anger disorder; the guidelines for screening and diagnosis; and discussion of the pharmacologic therapies that reduce core symptoms of the conditions. The presenter will address controversies in prescribing and the realities of clinical primary care management.